The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has recently approved chorproguanil/dapsone for the treatment of acute uncomplicated Plasmodium falciparum infections. It is registered as a once-daily, three-days treatment for use in all age groups (range of body weight 5-88kg). It will be marketed in most African countries by Glaxo-SmitKline (GSK) under the trade name “Lapdap”.

Reference:

DG News, http://main.pslgroup